About Callidus Biopharma
Callidus Biopharma is a company based in Doylestown (United States) founded in 2010 was acquired by Amicus Therapeutics in November 2013. Callidus Biopharma has raised $4.61 million across 1 funding round from investors including Amicus Therapeutics. Callidus Biopharma operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter Doylestown, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Callidus Biopharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.61 M (USD)
in 1 rounds
-
Latest Funding Round
$4.61 M (USD), Series A
Apr 12, 2013
- Investors
-
Employee Count
Not available
-
Acquired by
Amicus Therapeutics
(Nov 20, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Callidus Biopharma
Callidus Biopharma has successfully raised a total of $4.61M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.61 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Callidus Biopharma
Callidus Biopharma has secured backing from 1 investor. Prominent investors backing the company include Amicus Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of therapies for rare and orphan diseases
|
Locked | Locked | Locked |
Investor details for Callidus Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Callidus Biopharma
Investment portfolio details for Callidus Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Callidus Biopharma
Detailed financials for Callidus Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Callidus Biopharma Comparisons
Peer comparison for Callidus Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Callidus Biopharma
Callidus Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
Detailed competitors of Callidus Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Callidus Biopharma
Complete news archive for Callidus Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Callidus Biopharma
Callidus Biopharma was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Callidus Biopharma is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Callidus Biopharma is a funded company, having raised a total of $4.61M across 1 funding round to date.
Callidus Biopharma is a drug discovery company focused on best-in-class enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Callidus novel technology platform is based on attaching a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body. The companys therapeutics offer the potential to significantly reduce the amount of drug that needs to be infused, which translates to patient and medical benefits of better efficacy, shorter infusion times, reduced immunogenicity, and greater convenience. Our lead program is for Pompe Disease but we are also applying our IGF2 technology to other LSDs to improve drug targeting and efficacy. We have also created a more stable enzyme which has the potential to be a superior ERT for Gaucher Disease.
Callidus Biopharma's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Callidus Biopharma has 1 investor. Key investors include Amicus Therapeutics.